MedPath

BMS-986158

Generic Name
BMS-986158
Drug Type
Small Molecule
Chemical Formula
C30H33N5O2
CAS Number
1800340-40-2
Unique Ingredient Identifier
X8BW0MQ5PI
Background

BMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).

Clinical Trials
Related News

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1
Recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2022-05-12
Last Posted Date
2025-03-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
160
Registration Number
NCT05372354
Locations
🇺🇸

UAB Comprehensive Cancer Center, Birmingham, Alabama, United States

🇨🇦

University of Alberta - Cross Cancer Institute, Edmonton, Alberta, Canada

🇪🇸

ICO - Hospital Germans Trias i Pujol, Barcelona, Spain

and more 14 locations

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Phase 1
Active, not recruiting
Conditions
Myelofibrosis
Interventions
First Posted Date
2021-03-25
Last Posted Date
2025-02-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
216
Registration Number
NCT04817007
Locations
🇫🇷

Local Institution - 0010, Villejuif, France

🇺🇸

Local Institution - 0069, Newport Beach, California, United States

🇺🇸

Local Institution - 0090, Lake Mary, Florida, United States

and more 50 locations

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Phase 1
Completed
Conditions
Brain Tumor, Pediatric
Solid Tumor, Childhood
Lymphoma
Interventions
First Posted Date
2019-05-03
Last Posted Date
2024-10-02
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
41
Registration Number
NCT03936465
Locations
🇨🇦

Hospital for Sick Children, Toronto, Ontario, Canada

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 3 locations

Study of BMS-986158 in Subjects With Select Advanced Cancers

Phase 1
Completed
Conditions
Advanced Tumors
Interventions
Biological: Nivolumab
First Posted Date
2015-04-17
Last Posted Date
2022-06-16
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
83
Registration Number
NCT02419417
Locations
🇺🇸

Univ. Of Pa, Philadelphia, Pennsylvania, United States

🇺🇸

City Of Hope National Medical Center, Duarte, California, United States

🇺🇸

Institute for Translational Oncology Research-ITOR, Greenville, South Carolina, United States

and more 9 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy